Profile data is unavailable for this security.
About the company
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
- Revenue in GBP (TTM)2.91m
- Net income in GBP-4.97m
- Incorporated2018
- Employees36.00
- LocationGenincode PLC1 St. Peters SquareOXFORD OX4 4GPUnited KingdomGBR
- Phone+44 186 595 5847
- Websitehttps://www.genincode.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXS International plc | 3.42m | -194.92k | 800.28k | 61.00 | -- | 3.05 | -- | 0.2337 | -0.0031 | -0.0031 | 0.0535 | 0.0041 | 1.64 | -- | 6.83 | 56,127.87 | -9.35 | -14.79 | -15.93 | -17.90 | 86.70 | 87.06 | -5.69 | -22.80 | -- | -4.14 | 0.00 | -- | 4.88 | 1.13 | 98.00 | -- | -- | -- |
| TSP Advanced Technologies PLC | 0.00 | -653.36k | 936.50k | 1.00 | -- | 0.4455 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0112 | 0.00 | -- | -- | 0.00 | -17.99 | -19.94 | -28.78 | -25.43 | -- | -- | -- | -- | -- | -386.08 | 0.1311 | -- | -- | -- | -29.92 | -- | -41.11 | -- |
| Image Scan Holdings Plc | 1.62m | -288.02k | 1.92m | 13.00 | -- | 1.34 | -- | 1.18 | -0.0021 | -0.0021 | 0.0118 | 0.0105 | 0.6459 | 1.75 | 2.43 | -- | -11.50 | 0.0905 | -17.47 | 0.1358 | 58.50 | 52.65 | -17.80 | 0.0917 | 1.85 | -- | 0.0616 | 0.00 | -43.45 | -14.23 | -239.13 | -- | 34.92 | -- |
| Genincode PLC | 2.91m | -4.97m | 3.30m | 36.00 | -- | 1.24 | -- | 1.13 | -0.0232 | -0.0232 | 0.0137 | 0.0093 | 0.6562 | 15.74 | 2.87 | 80,944.45 | -111.87 | -- | -164.53 | -- | 53.02 | -- | -170.49 | -- | 2.73 | -10.96 | 0.0669 | -- | 25.05 | -- | 36.80 | -- | -- | -- |
| Surgical Innovations Group Plc | 11.92m | -1.44m | 4.20m | 88.00 | -- | 0.4903 | -- | 0.3523 | -0.0015 | -0.0015 | 0.0128 | 0.0092 | 0.9314 | 2.91 | 4.72 | 135,397.70 | -11.22 | -7.76 | -14.17 | -9.60 | 27.89 | 29.97 | -12.04 | -11.66 | 0.9524 | 8.46 | 0.0987 | -- | -0.5743 | 2.16 | -281.73 | -- | -8.28 | -- |
| Cambridge Nutritional Sciences PLC | 8.06m | 1.37m | 4.76m | 84.00 | 3.50 | 0.4305 | 2.38 | 0.5905 | 0.0057 | 0.0057 | 0.0338 | 0.0465 | 0.6153 | 3.59 | 3.57 | 95,940.48 | 10.42 | -3.22 | 11.69 | -3.67 | 66.44 | 58.85 | 16.94 | -7.21 | 3.79 | -- | 0.021 | -- | -14.77 | -3.23 | 577.44 | -- | -29.24 | -- |
| Feedback plc | 885.62k | -7.32m | 4.89m | 28.00 | -- | 0.7925 | -- | 5.52 | -0.2618 | -0.2618 | 0.0309 | 0.1407 | 0.1174 | -- | 9.83 | 31,629.29 | -96.97 | -38.54 | -105.98 | -41.65 | 87.92 | 90.05 | -826.25 | -435.27 | -- | -- | 0.00 | -- | -25.05 | 14.50 | -121.85 | -- | -1.14 | -- |
| Proteome Sciences plc | 4.53m | -3.33m | 6.05m | 36.00 | -- | -- | -- | 1.34 | -0.0113 | -0.0113 | 0.0153 | -0.0291 | 0.5087 | 5.92 | 5.75 | 125,750.00 | -37.44 | -8.02 | -- | -- | 17.43 | 45.80 | -73.60 | -15.07 | 0.0774 | -2.51 | 2.26 | -- | -2.80 | 0.9731 | -39.42 | -- | 31.03 | -- |
| Rua Life Sciences PLC | 5.17m | -850.00k | 9.00m | 33.00 | -- | 1.26 | -- | 1.74 | -0.0137 | -0.0137 | 0.0832 | 0.1151 | 0.5459 | 1.18 | 6.23 | -- | -9.18 | -- | -10.42 | -- | 77.10 | -- | -16.82 | -- | 3.87 | -- | 0.0995 | -- | -- | -- | -- | -- | -- | -- |
| Genedrive PLC | 954.00k | -5.23m | 10.81m | 43.00 | -- | 4.56 | -- | 11.33 | -0.0093 | -0.0093 | 0.0017 | 0.0023 | 0.1984 | -- | 1.80 | 22,186.05 | -108.81 | -77.52 | -153.92 | -106.30 | -- | -- | -548.32 | -1,016.12 | 1.64 | -- | 0.00 | -- | 90.42 | -2.07 | 26.06 | -- | -10.48 | -- |
| Verici DX PLC | 1.40m | -5.56m | 10.91m | 15.00 | -- | 0.9642 | -- | 7.81 | -0.0229 | -0.0229 | 0.0058 | 0.0075 | 0.2298 | -- | 1.67 | 77,631.66 | -91.48 | -- | -119.40 | -- | 81.60 | -- | -398.12 | -- | -- | -- | 0.102 | -- | 229.62 | -- | 32.75 | -- | -- | -- |
| Cellbxhealth PLC | 2.62m | -15.78m | 11.96m | 119.00 | -- | 0.2897 | -- | 4.56 | -0.0489 | -0.0489 | 0.0081 | 0.0362 | 0.1028 | 0.5939 | 1.46 | 22,050.42 | -61.80 | -41.90 | -72.78 | -46.81 | 62.27 | 18.55 | -601.37 | -1,051.13 | 2.63 | -470.57 | 0.2387 | -- | 30.92 | -- | 29.34 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 21 Jan 2026 | 52.88m | 18.43% |
| Chelverton Asset Management Ltd.as of 31 Dec 2024 | 8.85m | 3.08% |
| Santander Private Banking Gestion SA SGIICas of 31 Dec 2025 | 2.22m | 0.77% |
| Foresight Group LLP (Investment Management)as of 30 Sep 2025 | 1.69m | 0.59% |
| Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025 | 1.20m | 0.42% |
